专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US4067285A Modular floating structure 失效
标题翻译：模块化浮动结构
公开(公告)号：US4067285A
公开(公告)日：1978-01-10
申请号：US676756
申请日：1976-04-14
申请人： Robert M. Jones , Don E. Johnson
发明人： Robert M. Jones , Don E. Johnson
IPC分类号： B63B5/18 , B63B9/06 , B63B35/38 , B63B35/44 , B63B38/00
CPC分类号： B63B9/065 , B63B35/38 , B63B35/4413 , B63B38/00 , B63B5/18
摘要： This invention provides a floating structure made up of a plurality of individual modules, each of which has conduits extending through its walls. Tension members are threaded through the conduits and placed under tension to hold the modules together in a rigid assembly. Fasteners also may be used in securing the walls together, along with complementary aligning means to assure that the modules are held in a predetermined relationship.
摘要翻译：本发明提供了由多个单独的模块组成的浮动结构，每个单独的模块具有延伸穿过其壁的导管。张紧构件穿过导管并被放置在张力下以将模块保持在刚性组件中。紧固件还可以用于将壁固定在一起，以及互补的对准装置，以确保模块保持预定的关系。

72. 发明申请

US20140051714A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto 审中-公开
标题翻译： GPR119受体的调节剂和与之相关的疾病的治疗
公开(公告)号：US20140051714A1
公开(公告)日：2014-02-20
申请号：US14113081
申请日：2012-04-20
申请人： Robert M. Jones
发明人： Robert M. Jones
IPC分类号： C07D401/14 , A61K45/06 , A61K31/506
CPC分类号： C07D401/14 , A61K31/506 , A61K45/06
摘要： The present invention relates to the GPR119 agonist, 4-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yloxy)-5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidine (Compound 1): and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing the secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.
摘要翻译：本发明涉及GPR119激动剂，4-（1-（5-乙基嘧啶-2-基）哌啶-4-基氧基）-5-氟-6-（2-甲基-6-（甲基磺酰基）吡啶基氧基）嘧啶（化合物1）及其药学上可接受的盐，溶剂合物和水合物，其可用作单一药剂或与一种或多种另外的药剂如DPP-IV抑制剂，双胍类， α-葡萄糖苷酶抑制剂，胰岛素类似物，磺酰脲类，SGLT2抑制剂，氯噻嗪，噻唑烷二酮或抗糖尿病肽类似物，用于治疗例如选自以下的病症：GPR119-受体相关病症; 通过增加肠降血糖素的分泌而改善的状况; 通过增加血液肠降血糖水平来改善病情; 以低骨量为特征的病症; 神经障碍代谢相关疾病; 2型糖尿病; 肥胖; 和相关的并发症。

73. 发明授权

US08030270B2 Methods for identifying GLP-1 secretagogues 失效
标题翻译：识别GLP-1促分泌素的方法
公开(公告)号：US08030270B2
公开(公告)日：2011-10-04
申请号：US12610674
申请日：2009-11-02
申请人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
发明人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
IPC分类号： A61K38/00 , A61K51/00
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
摘要翻译：本发明涉及一定量的GPR119激动剂与二肽基肽酶IV（DPP-IV）抑制剂的量的组合，使得该组合提供降低血糖水平或增加血液GLP-1水平的效果受限于GPR119激动剂的量或单独的DPP-IV抑制剂的量以及这样的组合用于治疗或预防糖尿病和与之相关的病症或通过增加血液GLP-1水平而改善的病症。本发明还涉及G蛋白偶联受体筛选GLP-1促分泌素的用途。

74. 发明授权

US08022034B2 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level 失效
标题翻译：用于治疗糖尿病和与之有关的病症的组合疗法以及通过增加血液GLP-1水平而改善的病症的治疗
公开(公告)号：US08022034B2
公开(公告)日：2011-09-20
申请号：US12610877
申请日：2009-11-02
申请人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
发明人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
IPC分类号： A61K30/00 , A61K51/00
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
摘要翻译：本发明涉及一定量的GPR119激动剂与二肽基肽酶IV（DPP-IV）抑制剂的量的组合，使得该组合提供降低血糖水平或增加血液GLP-1水平的效果受限于GPR119激动剂的量或单独的DPP-IV抑制剂的量以及这样的组合用于治疗或预防糖尿病和与之相关的病症或通过增加血液GLP-1水平而改善的病症。本发明还涉及G蛋白偶联受体筛选GLP-1促分泌素的用途。

75. 发明授权

US07902153B2 Alpha-conotoxin peptides 有权
标题翻译： α-芋螺毒素肽
公开(公告)号：US07902153B2
公开(公告)日：2011-03-08
申请号：US12706911
申请日：2010-02-17
申请人： Maren Watkins , Baldomero M. Olivera , David R. Hillyard , J. Michael McIntosh , Robert M. Jones
发明人： Maren Watkins , Baldomero M. Olivera , David R. Hillyard , J. Michael McIntosh , Robert M. Jones
IPC分类号： A61K38/17 , C07K14/435
CPC分类号： C07K14/43504 , A61K38/00 , C07K7/08 , C07K9/00 , Y10S530/855 , Y10S530/857
摘要： The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
摘要翻译：本发明涉及相对较短的肽（本文称为α-芋螺毒素），长度约10-30个残基，其在锥形蜗牛的毒液中天然可以微量天然存在或类似于天然可得的肽，并且优选包括两个二硫键。

76. 发明申请

US20100286168A1 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL 审中-公开
公开(公告)号：US20100286168A1
公开(公告)日：2010-11-11
申请号：US12610885
申请日：2009-11-02
申请人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
发明人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
IPC分类号： A61K31/497 , A61K31/505 , A61P3/10
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.

77. 发明申请

US20100285494A1 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL 审中-公开
公开(公告)号：US20100285494A1
公开(公告)日：2010-11-11
申请号：US12610490
申请日：2009-11-02
申请人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
发明人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
IPC分类号： G01N33/53
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.

78. 发明申请

US20100253160A1 Over-Molded Liquid Cooled Three-Stack Motor 有权
标题翻译：超模冷液三层电机
公开(公告)号：US20100253160A1
公开(公告)日：2010-10-07
申请号：US12754476
申请日：2010-04-05
申请人： Robert M. Jones , Joseph M. Lisiecki
发明人： Robert M. Jones , Joseph M. Lisiecki
IPC分类号： H02K16/00 , H02K1/04 , H02P6/14 , H02K5/18 , H02K5/20 , H02K15/085 , H02K15/12
CPC分类号： H02K16/00 , H02K1/185 , H02K3/32 , H02K5/225 , H02K9/22 , H02K11/33 , H02K29/08 , H02P5/747 , Y10T29/49009
摘要： A brushless, liquid or air cooled, direct current motor formed from a three stack stator and three section rotor assembly using an integrated water cooled or air cooled housing and over-molding techniques.
摘要翻译：由三层定子和三段式转子组件形成的无刷，液体或空气冷却的直流电动机，其使用集成的水冷或空气冷却的壳体和过度成型技术。

79. 发明授权

US07803754B2 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level 有权
标题翻译：用于治疗糖尿病和与之有关的病症的组合疗法以及通过增加血液GLP-1水平而改善的病症的治疗
公开(公告)号：US07803754B2
公开(公告)日：2010-09-28
申请号：US11603417
申请日：2006-11-22
申请人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
发明人： Zhi-Liang Chu , James N. Leonard , Hussien A. Al-Shamma , Robert M. Jones
IPC分类号： A61K38/00 , A61K51/00
CPC分类号： G01N33/76 , A61K31/00 , A61K31/401 , A61K31/415 , A61K31/4196 , A61K45/06 , G01N33/74 , G01N2333/726 , G01N2800/042 , G01N2800/2814 , G01N2800/2835 , G01N2800/2857 , G01N2800/2871 , A61K2300/00
摘要： The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
摘要翻译：本发明涉及一定量的GPR119激动剂与二肽基肽酶IV（DPP-IV）抑制剂的量的组合，使得该组合提供降低血糖水平或增加血液GLP-1水平的效果受限于GPR119激动剂的量或单独的DPP-IV抑制剂的量以及这样的组合用于治疗或预防糖尿病和与之相关的病症或通过增加血液GLP-1水平而改善的病症。本发明还涉及G蛋白偶联受体筛选GLP-1促分泌素的用途。

80. 发明授权

US07666840B2 α-Conotoxin peptides 失效
标题翻译： α-芋螺毒素肽
公开(公告)号：US07666840B2
公开(公告)日：2010-02-23
申请号：US11869480
申请日：2007-10-09
申请人： Maren Watkins , Baldomero M. Olivera , David R. Hillyard , J. Michael McIntosh , Robert M. Jones
发明人： Maren Watkins , Baldomero M. Olivera , David R. Hillyard , J. Michael McIntosh , Robert M. Jones
IPC分类号： A61K38/10 , A61K38/17 , C07K7/08 , C07K14/435
CPC分类号： C07K14/43504 , A61K38/00 , C07K7/08 , C07K9/00 , Y10S530/855 , Y10S530/857
摘要： The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
摘要翻译：本发明涉及相对较短的肽（本文称为α-芋螺毒素），长度约10-30个残基，其在锥形蜗牛的毒液中天然可以微量天然存在或类似于天然可得的肽，并且优选包括两个二硫键。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式